Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 9
May 11 2021
Issue Cover

Table of Contents

STIMULUS REPORTS

Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice
Joana Campos,Tatyana Ponomaryov,Alexandra De Prendergast,Katharine Whitworth,Christopher W. Smith,Abdullah O. Khan,Dean Kavanagh,Alexander Brill
View Article
Supplemental data
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice
Archana Shrestha,Mengna Chi,Kimberly Wagner,Astha Malik,Jennifer Korpik,Adam Drake,Keertik Fulzele,Sylvie Guichard,Punam Malik
View Article
Supplemental data

SYSTEMATIC REVIEW

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
Clinical Trials & Observations
Edward J. Bataillard,Chan Yoon Cheah,Matthew J. Maurer,Arushi Khurana,Toby A. Eyre,Tarec Christoffer El-Galaly
View Article
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Clinical Trials & Observations
Cécile Tomowiak,Stéphanie Poulain,Charles Herbaux,Aurore Perrot,Béatrice Mahé,Pierre Morel,Thérèse Aurran,Olivier Tournilhac,Stéphane Leprêtre,Souad Assaad,Bruno Villemagne,Olivier Casasnovas,Delphine Nollet,Damien Roos-Weil,Sylvie Chevret,Véronique Leblond,on behalf of the FILO Group
View Article
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease
Clinical Trials & Observations
Alexis Leonard,Akshay Sharma,Naoya Uchida,David Stroncek,Sandhya R. Panch,Kamille West,Eoghan Molloy,Thomas E. Hughes,Sara Hauffe,Tiffani Taylor,Courtney Fitzhugh,Jane S. Hankins,Megan Wilson,Shengdar Q. Tsai,Mitchell J. Weiss,Matthew Hsieh,John F. Tisdale
View Article
Supplemental data

LYMPHOID NEOPLASIA

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death
Eva De Smedt,Julie Devin,Catharina Muylaert,Nicolas Robert,Guilhem Requirand,Philip Vlummens,Laure Vincent,Guillaume Cartron,Ken Maes,Jerome Moreaux,Elke De Bruyne
View Article
Supplemental data
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Clinical Trials & Observations
J. J. Eertink,C. N. Burggraaff,M. W. Heymans,U. Dührsen,A. Hüttmann,C. Schmitz,S. Müller,P. J. Lugtenburg,S. F. Barrington,N. G. Mikhaeel,R. Carr,S. Czibor,T. Györke,L. Ceriani,E. Zucca,M. Hutchings,L. Kostakoglu,A. Loft,S. Fanti,S. E. Wiegers,S. Pieplenbosch,R. Boellaard,O. S. Hoekstra,J. M. Zijlstra,H. C. W. de Vet
View Article
Supplemental data
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Stephan R. Bohl,Laura K. Schmalbrock,Imke Bauhuf,Tatjana Meyer,Anna Dolnik,Martin Szyska,Tamara J. Blätte,Sarah Knödler,Linda Röhner,Denise Miller,Miriam Kull,Christian Langer,Hartmut Döhner,Anthony Letai,Frederik Damm,Dirk Heckl,Lars Bullinger,Jan Krönke
View Article
Supplemental data

MYELOID NEOPLASIA

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis
David J. Young,Bao Nguyen,Ruiqi Zhu,Jaesung Seo,Li Li,Mark J. Levis,Keith W. Pratz,Amy S. Duffield,Donald Small
View Article
Supplemental data
LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα
Kensaku Kohrogi,Shinjiro Hino,Akihisa Sakamoto,Kotaro Anan,Ryuta Takase,Hirotaka Araki,Yuko Hino,Kazutaka Araki,Tetsuya Sato,Kimitoshi Nakamura,Mitsuyoshi Nakao
View Article
Supplemental data
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
Allison J. Kaeding,Sonali P. Barwe,Anilkumar Gopalakrishnapillai,Rhonda E. Ries,Todd A. Alonzo,Robert B. Gerbing,Colin Correnti,Michael R. Loken,Lisa Eidenschink Broderson,Laura Pardo,Quy H. Le,Thao Tang,Amanda R. Leonti,Jenny L. Smith,Cassie K. Chou,Min Xu,Tim Triche, Jr,Steven M. Kornblau,E. Anders Kolb,Katherine Tarlock,Soheil Meshinchi
View Article
Supplemental data
SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD–mutant AML
Suruchi Pacharne,Oliver M. Dovey,Jonathan L. Cooper,Muxin Gu,Mathias J. Friedrich,Sandeep S. Rajan,Maxim Barenboim,Grace Collord,M. S. Vijayabaskar,Hannes Ponstingl,Etienne De Braekeleer,Ruben Bautista,Milena Mazan,Roland Rad,Konstantinos Tzelepis,Penny Wright,Malgorzata Gozdecka,George S. Vassiliou
View Article
Supplemental data

PLATELETS AND THROMBOPOIESIS

CRISPR-edited megakaryocytes for rapid screening of platelet gene functions
Emilie Montenont,Seema Bhatlekar,Shancy Jacob,Yasuhiro Kosaka,Bhanu K. Manne,Olivia Lee,Ivan Parra-Izquierdo,Emilia Tugolukova,Neal D. Tolley,Matthew T. Rondina,Paul F. Bray,Jesse W. Rowley
View Article
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency
Clinical Trials & Observations
Marja W. Wessels,Marjon H. Cnossen,Thamar B. van Dijk,Nynke Gillemans,K. L. Juliëtte Schmidt,Kirsten van Lom,Divya S. Vinjamur,Steven Coyne,Ryo Kurita,Yukio Nakamura,Stella A. de Man,Rolph Pfundt,Zakia Azmani,Rutger W. W. Brouwer,Daniel E. Bauer,Mirjam C. G. N. van den Hout,Wilfred F. J. van IJcken,Sjaak Philipsen
View Article
Supplemental data

TRANSPLANTATION

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Clinical Trials & Observations
Michael Heuser,Bennet Heida,Konstantin Büttner,Clara Philine Wienecke,Katrin Teich,Carolin Funke,Maximilian Brandes,Piroska Klement,Alessandro Liebich,Martin Wichmann,Blerina Neziri,Anuhar Chaturvedi,Arnold Kloos,Konstantinos Mintzas,Verena I. Gaidzik,Peter Paschka,Lars Bullinger,Walter Fiedler,Albert Heim,Wolfram Puppe,Jürgen Krauter,Konstanze Döhner,Hartmut Döhner,Arnold Ganser,Michael Stadler,Lothar Hambach,Razif Gabdoulline,Felicitas Thol
View Article
Supplemental data
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Wright-stained peripheral blood smear from a Berkeley sickle cell disease mouse that received oral FT-4202 for 2 weeks, showing a significant reduction in irreversibly sickled cells. FT-4202 is an erythrocyte pyruvate kinase inhibitor that decreases 2,3-diphosphoglycerate and increases red blood cell ATP levels to reduce sickling. See the article by Shrestha et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma
Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright ©2023 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement